StemCell Therapy

Promising results were observed in a small, single-arm, phase 2 studyevaluating the efficacy and safety of the programmed cell death-1 (PD-1)inhibitor, pembrolizumab, plus radiation therapy (RT) in patients with locallyadvanced head and neck cancers who were ineligible to receive cisplatin-basedchemoradiation therapy. These findings were presented during the 2020Multidisciplinary Head and Neck Cancers Symposium in Scottsdale, Arizona.

Cisplatin-based chemoradiation therapyis considered a standard of care for the treatment of locally advanced squamouscell carcinoma of the head and neck (LA-HNSCC), with cisplatin acting as both achemotherapeutic agent and a sensitizer to ionizing radiation. However, it isnot uncommon for patients to have contraindications to the receipt of cisplatintherapy, thereby necessitating selection of another radiosensitizer forconcomitant use with RT.

The choice of pembrolizumab as asubstitute for cisplatin in the setting of LA-HNSCC was based, in part, onprevious studies showing that radiation elicitsand promotes tumor-directed immune-stimulation, which may potentiate antiPD-1therapy, the study authors commented.

None of the 29 adult patients enrolled in this study (ClinicalTrials.gov Identifier: NCT02609503) had undergone prior curative treatment for LA-HNSCC, and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 was a study inclusion criterion. Pembrolizumab was administered concurrently with RT every 3 weeks for 3 cycles followed by 3 cycles of pembrolizumab. The primary study endpoint was progression-free survival (PFS), with overall survival (OS) and safety included as secondary study endpoints.

Twenty patients hadcancers of the tongue or tonsil, with a variety of other sites of disease,including supraglottic larynx and hypopharynx, present in the remaining patients.Nonmetastatic stage III or IV disease was present in approximately three-quartersof study patients. Reasons for ineligibility to receive cisplatin includedotopathology (69.0%), nephropathy (20.7%), and neuropathy (6.9%).

One-yearrates of PFS and OS for the overall study population were 76% and 86%,respectively. Furthermore, at a median follow-up of 21 months, the median PFShad not been reached and exceeded the hypothesized median PFS of 16 months,leading study authors to conclude that this approach deserves evaluation in arandomized trial.

Whilerespective 1-year PFS and OS rates were 88% and 94% for patients with p16/humanpapilloma virus (HPV)-positive cancers of the oropharynx, the correspondingrates were 58% and 75% for those with other type of LA-HNSCC.

Although the presence of programmed celldeath-ligand 1 (PD-L1)positive disease was not found to be associated withlikelihood of disease progression, the relative percentages of specific B-cellpopulations, such as a higher percentage of baseline naive B-cells and a lowerpercentage of marginal zone B cells, were associated with an increased risk ofprogressive disease.

Toxicitiesfrequently associated with administration of RT were observed, although grade 3or grade 4 lymphopenia was observed in over half of the study patients.

In their concluding remarks, the study authors stated that concurrent pembrolizumab and radiotherapy has demonstrated promising PFS and OS in LA-HNSCC, regardless of p16 status or anatomic location, with a favorable toxicity profile.

Disclosure: Some of the authors of theabstract disclosed financial relationships with pharmaceutical companies,medical device companies, and/or health-related companies. For a full list ofdisclosures, please refer to the abstract.

Reference

Weiss J, Vincent B, Deal A, et al. Progression-free survival, overall survival and immunophenotyping outcomes for patients with stage III-IV head and neck cancer and cisplatin contraindication treated immunophenotyping outcomes for patients with stage III-IV head and neck cancer and cisplatin contraindication treated with definitive radiotherapy plus pembrolizumab. Presented at: Multidisciplinary Head and Neck Cancers Symposium; February 27-29, 2020; Scottsdale, AZ. Abstract LBA1.

See original here:
Promising Clinical Activity for RT Plus ICIs in Locally Advanced Head and Neck Cancers - Cancer Therapy Advisor

DEAR DR. ROACH: Im a 63-year-old male diagnosed with chronic myelogenous leukemia, Type 2 diabetes and coronary heart disease. I am 5 feet, 11 inches and weigh 240 pounds. I have two stents and take Sprycel for the CML. My levels are good, and the coronary disease is under control.

For a few years Ive had what feels like cotton balls under the skin in the area of the balls of my feet. Now it feels like its migrating to the arch. While not too uncomfortable, it is almost impossible to walk barefooted. Some type of foot covering is needed to keep from noticing the feeling. My doctor says its the diabetes, and to lose weight or see a podiatrist. Other than losing the weight, do you have any opinion about this? N.M.

ANSWER: Cotton-ball sensation is one way that many people describe the beginning of neuropathy, a general term for a variety of different conditions that affect the nerves of the body.

In a person with cancer (like CML, chronic myelogenous leukemia, a cancer of the bone marrow) and a new symptom, it is always wise to consider whether it could be due to the cancer, the treatment for the cancer or from something else. In your case, usually CML is not associated with neuropathy. However, the medicine you are taking, dasatinib (Sprycel), has been associated with a severe kind of reversible neuropathy. I read the case reports of this condition carefully, and I doubt that is what is going on with you, as the symptoms you have are different from those reported.

People with longstanding diabetes frequently develop a particular disease of the nerves, diabetic neuropathy. This almost always begins with sensation changes in the feet. I agree with your doctor that diabetes is the most likely cause.

Seeing a podiatrist is absolutely a good idea. He or she can test you for this condition (usually a careful physical exam will make the diagnosis), in addition to looking carefully for any early signs or risk factors for injury or infection. You also should learn how to do a daily inspection of your feet and recognize the signs, so you can get to medical attention promptly should any damage to your feet occur. The podiatrist will make sure you have appropriate footwear.

Many people with diabetes benefit from weight loss, but the important thing is to be sure your diabetes is under good control. This is achieved through good diet, regular exercise and medication, if needed, in addition to weight loss in people who are overweight.

DEAR DR. ROACH: Due to cancer, my prostate was removed about seven years ago. My PSA reading has increased since 2012 from 0.09 to 0.304. Should I be concerned? I am 78 years old and in relatively good health. B.D.

ANSWER: PSA readings can go up and down, but a threefold increase could mean that the cancer is coming back, and you should see the specialist taking care of your prostate cancer to discuss getting additional testing.

Not having disease for seven years after treatment is a good sign, but the PSA test is pretty specific for cancer recurrence if two separate readings are above 0.2. You may need additional therapy, but only further investigation will show how concerned you need to be.

Dr. Roach regrets that he is unable to answer individual questions, but will incorporate them in the column whenever possible. Readers may email questions to ToYourGoodHealth@med.cornell.edu.

Go here to see the original:
'Cotton ball' sensation is a sign of neuropathy - Coastal Courier

For breast cancer patients, the adverse effects of the cancer and its treatments do not cease when the disease leaves the body, and well-being remains affected. A new study found that older breast cancer survivors live with a higher level of actionable symptoms and greater loss of wellbeing over time compared to patients without cancer.

According to the authors, they undertook the study because there is little research regarding the long-term symptom burden carried by this population, as well as how this burden affects overall well-being and if lifestyle interventions influence it.

The study focused on breast cancer survivors aged 60 years with newly diagnosed, nonmetastatic breast cancer, who were compared to noncancer controls. Recruitment took place between August 2010 and June 2016. The following parameters were used to measure symptom burden: pain (yes or no), fatigue (on the Functional Assessment of Cancer Therapy [FACT]Fatigue scale), cognitive problems (on the FACTCognitive scale), sleep problems (yes or no), depression (on the Center for Epidemiologic Studies Depression scale), anxiety (on the StateTrait Anxiety Inventory), and cardiac problems and neuropathy (yes or no). A 100-point FACT-General scale was used to determine well-being. Lifestyle was assessed by factors including smoking, alcohol use, body mass index, physical activity, and leisure activities. Correlations were analyzed between treatment group (chemotherapy with or without hormone therapy, hormone therapy only, and controls) and symptom burden, lifestyle, and covariates; further analyses assessed how fluctuations in symptom burden and lifestyle affected function.

Symptoms were high at baseline across the whole cohort. The most significant differences between the cancer survivors and controls were observed in cognitive problems, sleep problems, anxiety, and neuropathy. In adjusted analyses, survivors who had undergone chemotherapy had the highest burden score, followed by those who had received hormone therapy, compared to controls (P<0.001). Factors that influenced the burden score were physical, emotional, and mental well-being; survivors with lower burden scores, compared to those with higher burden scores, had 12.4-point higher physical well-being scores. Lifestyle did not affect symptom burden or well-being, although physical activity played a large role in both (P<0.005).

The study was published in the March 15 issue of Cancer.

Cancer and its treatments are associated with a higher level of actionable symptoms and greater loss of wellbeing over time in older breast cancer survivors than in comparable noncancer populations, suggesting the need for surveillance and opportunities for intervention, summarized the study authors.

Read more from the original source:
Breast Cancer Survivors Suffer Greater Loss of Well-Being than Noncancer Patients Later in Life - DocWire News

Los Angeles, United State The report titled Global Neuropathy Pain Treatment Market Research Report 2020 is one of the most comprehensive and important additions to QY Researchs archive of market research studies. It offers detailed research and analysis of key aspects of the global Neuropathy Pain Treatment market. The market analysts authoring this report have provided in-depth information on leading growth drivers, restraints, challenges, trends, and opportunities to offer a complete analysis of the global Neuropathy Pain Treatment market. Market participants can use the analysis on market dynamics to plan effective growth strategies and prepare for future challenges beforehand. Each trend of the global Neuropathy Pain Treatment market is carefully analyzed and researched about by the market analysts.

Global Neuropathy Pain Treatment Market is valued at USD XX million in 2019 and is projected to reach USD XX million by the end of 2025, growing at a CAGR of XX% during the period 2019 to 2025.

Top Key Players of the Global Neuropathy Pain Treatment Market: Pfizer, Depomed, Eli Lilly, Endo, Grnenthal Group, Arbor Pharmaceuticals,

Download Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart): https://www.qyresearch.com/sample-form/form/1436343/global-neuropathy-pain-treatment-market

The Essential Content Covered in the Global Neuropathy Pain Treatment Market Report:

* Top Key Company Profiles.

* Main Business and Rival Information

* SWOT Analysis and PESTEL Analysis

* Production, Sales, Revenue, Price and Gross Margin

* Market Share and Size

Global Neuropathy Pain Treatment Market Segmentation By Product:

Calcium Channel Alpha 2-delta LigandsSerotonin-norepinephrine Reuptake InhibitorsOthers

Global Neuropathy Pain Treatment Market Segmentation By Application:

Retail PharmaciesHospitalsOthers

In terms of region, this research report covers almost all the major regions across the globe such as North America, Europe, South America, the Middle East, and Africa and the Asia Pacific. Europe and North America regions are anticipated to show an upward growth in the years to come. While Neuropathy Pain Treatment Market in Asia Pacific regions is likely to show remarkable growth during the forecasted period. Cutting edge technology and innovations are the most important traits of the North America region and thats the reason most of the time the US dominates the global markets. Neuropathy Pain Treatment Market in South, America region is also expected to grow in near future.

Key questions answered in the report

* What will be the market size in terms of value and volume in the next five years?

* Which segment is currently leading the market?

* In which region will the market find its highest growth?

* Which players will take the lead in the market?

* What are the key drivers and restraints of the markets growth?

Get Customized Report in your Inbox within 24 hours @https://www.qyresearch.com/customize-request/form/1436343/global-neuropathy-pain-treatment-market

Research Methodology

* Data triangulation and market breakdown

* Research assumptions Research data including primary and secondary data

* Primary data includes breakdown of primaries and key industry insights

* Secondary data includes key data from secondary sources

We provide detailed product mapping and analysis of various market scenarios. Our analysts are experts in providing in-depth analysis and breakdown of the business of key market leaders. We keep a close eye on recent developments and follow latest company news related to different players operating in the global Neuropathy Pain Treatment market. This helps us to deeply analyze companies as well as the competitive landscape. Our vendor landscape analysis offers a complete study that will help you to stay on top of the competition.

About Us:

We established as a research firm in 2007 and have since grown into a trusted brand amongst many industries. Over the years, we have consistently worked toward delivering high-quality customized solutions for wide range of clients ranging from ICT to healthcare industries. With over 50,000 satisfied clients, spread over 80 countries, we have sincerely strived to deliver the best analytics through exhaustive research methodologies.

Excerpt from:
Neuropathy Pain Treatment Market by Companies, Regions, Type and Application 2026| Pfizer, Depomed, Eli Lilly - Weekly Wall

Patients undergoing chemotherapy or radiation therapy at the SECU Comprehensive Cancer Center at CarolinaEast Medical Center can receive three complimentary oncology massage treatments.

Arnie Smalldridge, a former administrative assistant at CarolinaEast, said she was inspired to pursue oncology massage therapy training after seeing how massaging her mother-in-laws feet helped to relieve cancer pain.

She also served as secretary to a patient and family advisory where she heard cancer patients talk about what helped to relieve them from pain.

While we were building the foundation of the cancer center, there were two patients who said massage was the only thing that helped them to handle their pain, Smalldridge said. I knew then that I wanted to go back to school. I was just blessed that CarolinaEast opened up this position for me.

Smalldridge graduated from a massage therapy program at Lenoir Community College in 2017, received an online certificate of completion for oncology massage and in May completed 32 hours of hands-on oncology massage therapy training in Raleigh.

It definitely was a calling, she said. Ive always believed strongly in the power behind the human touch. Sometimes I have patients in here and they live alone. They dont really have a caregiver. Just having someone to touch them and soothe them in that manner, thats all they need. Its psycho-social, if you will.

About five patients a day receive 45-minute treatments in her massage room at the cancer center. The low lighting, relaxing music and aroma therapy helps them to relax, she said.

I sit down with them first and talk with them about their condition to better know what I need to do for them, Smalldridge said. When you do oncology massage therapy, you have to be very mindful of your pressure with an oncology patient. If there is a tumor site, you have to avoid that.

She said oncology massage therapy is different from typical massage therapy in that the therapist must know where the cancer is in the patients body, the types of treatment they are undergoing and any side effects theyre experiencing.

You have to know if the cancer has spread, especially if it has metastasized into the bone marrow, Smalldridge said. The bones can be so fragile that you really want to watch your pressure in that area. You want to avoid any tumor sites. But you do want to focus on the tissue in those areas where the pain is and just do a very light treatment on them to try to release those tissues.

She said oncology massage therapy helps patients to relax and manage their pain better without the use of many pain medications.

It helps their sleep, improves immune function, Smalldridge said. They get peripheral neuropathy relief from massage and they get relief from nausea. They have so many side effects from their medications as far as joint pain, inflammation. Massage helps with that as well.

Therapy also helps with patients undergoing radiation treatments, she said.

The radiation treatment targets the tumor site, but it also irradiates tissues around that site, Smalldridge said. Breast cancer patients can end up with frozen shoulders. Humans guard themselves from pain. You see this in breast cancer patients. They throw their shoulders forward, which messes up their entire gait.

Some patients fear the pain they feel means the cancer has spread or metastasized, she said.

What I do is I help them to understand that these are side effects, that its not a metastasized site, Smalldridge said.

She usually sees patients who are in treatment for cancer, but doctors have referred some patients to her who are three to five years out of treatment.

What I have seen there is that even in their survivor state, three to five years later, theyre still showing effects of the chemo treatment or the radiation treatment, Smalldridge said. They have to get used to the new normal.

Read the original:
CarolinaEast oncology massage therapist followed calling [sponsored content] - New Bern Sun Journal

The National Institutes of Health is coordinating panel discussions on Friday, February 28 in Bethesda, MD to improve diagnosis and treatment, expand clinical trial resources, and increase awareness of rare diseases.

In all, NORD lists over 400 events in 106 countries marking Rare Disease Day, including conferences, research presentations, exhibits, walks, rallies and a variety of fundraisers.

Rare Disease Day started in 2008 with the first events held in Canada and Europe. The date February 29 was chosen because it is rare (Rare Disease Day is on February 28 in non-leap years).

Rare diseases and disorders often go undiagnosed and untreated. Due to their rarity, expertise, treatment and resources are limited for people living with a rare disease, who can also face discrimination at work and school.

Research on rare diseases can actually help improve understanding of more common disorders and lead to new treatments. For instance, Yale neuroscientist Dr. Stephen Waxman discovered the gene SCN9A and its role in two painful hereditary neuropathies. Treatments for these disorders may help people with many other forms of peripheral neuropathy, as Waxman explains in his book, Chasing Men on Fire.

Moreover, rare diseases are often misunderstood. They do not look like typical illness and may require unusual forms of medical care. So Rare Disease Day also represents a chance to raise awareness about the importance of research, specialist centers, and healthcare professionals who work on such disorders.

Although most rare diseases do not have a cure, they can all be managed and patient lives improved. Rare Disease Day is an opportunity to focus on promising research, improving patients lives, and promoting action.

Roger Chriss lives with Ehlers Danlos syndrome and is a proud member of the Ehlers-Danlos Society. Roger is a technical consultant in Washington state, where he specializes in mathematics and research.

Here is the original post:
Be Strong and Proud on Rare Disease Day - Pain News Network

Chemotherapy Induced Peripheral Neuropathy Treatment market Research Report 2020 offers a comprehensive analysis of the market growth drivers, trends, opportunities, prospects, drivers and restrictions inside the market. The report emphasizes to meet the requirement of customers by providing complete knowledge of the Chemotherapy Induced Peripheral Neuropathy Treatment Industry. This carefully organised report is formulated by industry experts and professional experts, in terms of demand and supply, cost organization, barriers and challenges, product category, crucial market players, technology, regions, and applications.

The Chemotherapy Induced Peripheral Neuropathy Treatment market study is based on historical information and present market requirements. As well as includes different business approaches preferred by the decision-makers. That enhanced the Chemotherapy Induced Peripheral Neuropathy Treatment industry growth and make a phenomenal stand in the industry. The market will raise with a prominentCAGRby 2020 to 2025.

Download Free Sample Report

https://www.reportspedia.com/report/life-sciences/global-chemotherapy-induced-peripheral-neuropathy-treatment-market-2020-by-manufacturers,-regions,-type-and-application,-forecast-to-2025/49368 #request_sample

Furthermore, it also evaluates the most recent improvements while estimating the growth of theleading playerslike

Aptinyx Inc, Sova Pharmaceuticals Inc, MAKScientific LLC, Asahi Kasei Pharma Corp, PledPharma, Regenacy Pharmaceuticals, Immune Pharmaceuticals Inc, Nemus Bioscience Inc, Metys Pharmaceuticals AG, DermaXon LLC, WinSanTor, Kineta Inc, Solasia Pharma K.K., Apexian Pharma, Krenitsky Pharmaceuticals Inc, PeriphaGen,

Segmentation by Product Type

By TypeChemotherapy Induced Peripheral Neuropathy Treatment market has been segmented into Calcium Channel 2-delta Ligands, Antidepressants, Opioids, Others, etc.

Segmentation by Application/ End uses:

By Application Chemotherapy Induced Peripheral Neuropathy Treatment has been segmented into Platinum Agents, Taxanes, Vinca Alkaloids, Others, etc.

Regional Analysis for Chemotherapy Induced Peripheral Neuropathy Treatment Market:

North America (the United States, Canada & Rest of the countries)

Europe (Germany, The UK, France, Netherlands, Italy, Spain & the rest of the countries)

Asia-Pacific (China, Japan, Korea, India, & rest of the countries)

Middle East & Africa (South Africa, Israel, UAE & rest of the countries)

South America (Brazil, Colombia, Argentina & the rest of the countries)

Ask For discount

https://www.reportspedia.com/discount_inquiry/discount/49368>

What is the regional structure of the market? Our analysis-

The Chemotherapy Induced Peripheral Neuropathy Treatment Industry report analyses footprint of every product and its significance analyzes examine each geographical segment of the market with import, export, consumption, and production in these regions to provide a complete understanding of the Chemotherapy Induced Peripheral Neuropathy Treatment market

In addition, the Chemotherapy Induced Peripheral Neuropathy Treatment Industry report covers an analysis of different products available in the global market built on production, volume, revenue, and cost and price structure. The Chemotherapy Induced Peripheral Neuropathy Treatment Market report also highlights key strategies that proved to be profitable for the business in-line with the policies involved in business expansion, partnership deals, composition, and new product/service launches.

YEARS CONSIDERED FOR THIS REPORT:

Historical Years:2015-2019

Base Year:2019

Estimated Year:2020

Forecast Period:2020-2025

DEFINITE SEGMENTS OF GLOBAL Chemotherapy Induced Peripheral Neuropathy Treatment INDUSTRY:

The analysis highlights a region-wise as well as a worldwide study of the Chemotherapy Induced Peripheral Neuropathy Treatment market. Proportionately, the regional study of the industry comprisesJapan, South East Asia, India, the USA, Europe, and China.Moreover, the report reviews an in-depth market analysis of distinct manufacturers and suppliers. It explainsindustry chain structure, competitive scenario, and study of Chemotherapy Induced Peripheral Neuropathy Treatment industry costin detail. It evenly analyzes global industry size pursued by forecast period (2020-2025) and environment.

Ask For Report Customization

https://www.reportspedia.com/inquiry/customization/49368

The analysis covers basic information about the Chemotherapy Induced Peripheral Neuropathy Treatment product likeindustry scope, segmentation, anoverviewof the market. Likewise, it providessupply-demand data, investment feasibleness, and elements that limiting the growth of an industry. Predominantly, it helps product demand, annual revenue and growth prospects of the industry. The foreseen Chemotherapy Induced Peripheral Neuropathy Treatment market regions along with the present onesassist leading vendors, decision-makers, and viewers/readersto plan effective business strategies respectively.

KEY TOPIC COVERED

Growth Opportunities

Market Growth Drivers

Leading Market Players

Market Size and Growth Rate

Market Trend and Technological

Company Market Share

TOC OF Chemotherapy Induced Peripheral Neuropathy Treatment MARKET REPORT INCLUDES:

1 Industry Overview of Chemotherapy Induced Peripheral Neuropathy Treatment

2 Industry Chain Analysis

3 Manufacturing Technology

4 Major Manufacturers Analysis

5 Global Productions, Revenue and Price Analysis of Chemotherapy Induced Peripheral Neuropathy Treatment by Regions, Creators, Types, and Applications

6 Global and Foremost Regions Capacity, Production, Revenue and Growth Rate by 2013-2019

7 Consumption Volumes, Consumption Value, Import, Export and Sale Price Analysis by Regions

8 Gross and Gross Margin Analysis

9 Marketing Traders or Distributor Analysis

10 Global and Chinese Economic Impacts on the Chemotherapy Induced Peripheral Neuropathy Treatment Industry

11 Development Trend Analysis

12 Contact information

13 New Project Investment Feasibility Analysis

14 Conclusion of the Global Chemotherapy Induced Peripheral Neuropathy Treatment Industry 2019 Market Research Report Continued

Finally, the feasibility of new investment projects is assessed, and overall research conclusions are offered.

Key questions answered by the Chemotherapy Induced Peripheral Neuropathy Treatment Report:

What are some of the most favourable, high-growth prospects for the global Chemotherapy Induced Peripheral Neuropathy Treatment market?

Which products segments will raise at a faster pace throughout the forecast period and why?

What are the foremost factors impacting market prospects?

What are the driving factors, restraints, and challenges in this Chemotherapy Induced Peripheral Neuropathy Treatment market?

What are the competitive threats and challenges to themarket?

What are the evolving trends in this Chemotherapy Induced Peripheral Neuropathy Treatment market and reasons behind their emergence?

What are some of the changing customer demands in the Chemotherapy Induced Peripheral Neuropathy Treatment Industry market?

Continue

Explore More Information

https://www.reportspedia.com/report/life-sciences/global-chemotherapy-induced-peripheral-neuropathy-treatment-market-2020-by-manufacturers,-regions,-type-and-application,-forecast-to-2025/49368 #table_of_contents

See original here:
Global Chemotherapy Induced Peripheral Neuropathy Treatment Market 2020 Swot (Strengths, Weaknesses, Opportunities, And Threats) analysis By...

Asuman Celikbilek

Department of Neurology, Kudret International Hospital, Ankara, Turkey

Correspondence: Asuman CelikbilekKudret International Hospital, Department of Neurology, Ankara 06600, TurkeyTel +90 505 6532615Fax +90 312 229 98 68Email asunebioglu@yahoo.com

We read with great interest the article recently published in Journal of Pain Research by Sari et al,1 examining the effect of vitamin D replacement therapy on neuropathic pain and imbalance in patients with diabetic neuropathy (DN). They found that vitamin D replacement reduced neuropathic pain and improved balance scores in patients with DN. They suggested that a vitamin D replacement schedule might be planned in diabetic patients with vitamin D deficiency in order to resolve neuropathic pain and balance problems. However, we would like to add some points which may be taken into consideration.

View the original paper by Sari and colleagues

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Read more:
Possible Associations of Vitamin D, Vitamin D-Binding Protein, and Vit | JPR - Dove Medical Press

XMT-1536 Phase 1 dose escalation data update selected for late-breaker oral presentation at upcoming Society of Gynecologic Oncology (SGO) 2020 Annual Meeting on Womens Cancer

XMT-1536 interim Phase 1 dose expansion data to be presented in 2Q 2020 with more mature data expected in 2H 2020

Company to present preclinical data on ADCs created with the Dolasynthen and Immunosynthen platforms at the American Association for Cancer Research (AACR) Annual Meeting

CAMBRIDGE, Mass., Feb. 28, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today reported financial results and provided a business update for the fourth quarter and full year ended December 31, 2019.

We are excited to present updated data from our ongoing dose escalation study in heavily pre-treated and biomarker unselected patients at the upcoming SGO 2020 Annual Meeting on Womens Cancer. We plan to demonstrate that, at doses up to 43 mg/m2, XMT-1536 is well tolerated without the severe neutropenia, neuropathy or ocular toxicities typically observed with other ADC platforms, said Anna Protopapas, President and Chief Executive Officer of Mersana Therapeutics. Additionally, we continue to execute on our proof-of-concept expansion cohorts in ovarian and non-small cell lung cancer for XMT-1536 and are on track for additional data disclosures throughout the year. These data readouts will be important milestones as we chart a fast-to-market path to registration in ovarian cancer.

Recent Highlights and Updates

Clinical Programs

Discovery & Platform Progress

Upcoming First Quarter 2020 Events

2019 Financial Results

Cash, cash equivalents and marketable securities as of December 31, 2019, were $99.8 million, compared to $70.1 million as of December 31, 2018. In addition, the Company has the option to draw additional funds of up to $15.0 million through the existing debt financing agreement with Silicon Valley Bank. The Company expects that its current cash, cash equivalents and marketable securities will enable it to fund its operating plan through important milestones, including the XMT-1536 Phase 1 clinical study and the planned dose escalation study for XMT-1592.

Fourth Quarter 2019

Full Year 2019

Conference Call DetailsMersana Therapeutics will host a conference call and webcast today at 8:00 a.m. ET to report financial results for the fourth quarter and year-end of 2019 and provide certain business updates. To access the call, please dial 877-303-9226 (domestic) or 409-981-0870 (international) and provide the Conference ID 4849085. A live webcast of the presentation will be available on the Investors & Media section of the Mersana website at http://www.mersana.com.

About Mersana TherapeuticsMersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to rapidly develop novel ADCs with optimal efficacy, safety and tolerability to meaningfully improve the lives of people fighting cancer. Mersanas lead product candidate, XMT-1536, is in a Phase 1 proof-of-concept clinical trial in patients with tumors likely to express NaPi2b, including ovarian cancer and NSCLC adenocarcinoma. Mersanas second product candidate targeting NaPi2b-expressing tumors, XMT-1592, is an ADC created using Mersanas customizable and homogenous Dolasynthen platform. The Companys early stage programs include a B7-H4 targeting ADC, as well as a STING agonist ADC developed using the Companys Immunosynthen platform. In addition, multiple partners are using Mersanas Dolaflexin platform to advance their ADC pipelines.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of federal securities laws. These forward-looking statements are not statements of historical facts and are based on managements beliefs and assumptions and on information currently available to management. Forward-looking statements include information concerning the Companys business strategy and the design, progression and timing of its clinical trials. Forward-looking statements generally can be identified by terms such as anticipates, believes, could, seeks, estimates, intends, may, plans, potential, predicts, projects, should, will, would or similar expressions and the negatives of those terms. Forward-looking statements represent managements beliefs and assumptions only as of the date of this press release. The Companys operations involve risks and uncertainties, many of which are outside its control, and any one of which, or combination of which, could materially affect its results of operations and whether the forward-looking statements ultimately prove to be correct. Factors that may materially affect the Companys results of operations and whether these forward-looking statements prove to be correct include, among other things, that preclinical testing may not be predictive of the results or success of ongoing or later preclinical or clinical trials, that the development and testing of the Companys product candidates and new platforms will take longer and/or cost more than planned and that the identification of new product candidates will take longer than planned, as well as those listed in the Companys Annual Report on Form 10-K filed on February 28, 2020, with the Securities and Exchange Commission (SEC) and subsequent SEC filings. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

Mersana Therapeutics, Inc.Selected Condensed Consolidated Balance Sheet Data(in thousands)(unaudited)

Mersana Therapeutics, Inc.Condensed Consolidated Statement of Operations(in thousands, except share and per share data)(unaudited)

Contact:

Investor & Media ContactSarah Carmody, 617-844-8577scarmody@mersana.com

Read the original here:
Mersana Therapeutics Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Business Updates - BioSpace

February 2020

Are you looking for a health care provider who offers innovative alternatives and a customized approach to your health issues? Indiana Regenerative Medicine Institute (IRMI) believes in offering specialized alternatives to health care. Its medical team, headed by Doctor of Chiropractic Preston Peachee, utilizes the latest developments in regenerative medicine, hormone replacement and pain management.

Dr. Peachee is a native of Jasper, Indiana. He graduatedfrom Logan College of Chiropractic and has been in practice since 2003. Hisareas of specialty include patients with chronic and severe back, neck andjoint pain as well as other complex neurological conditions.

Dr. Peachee has earned a reputation as an innovative thinkeras well as a compassionate practitioner who brings his wide expertise andexperience to the Greater Indianapolis area. His ability to help those in needof regenerative medicine, neuropathy pain relief, low testosterone or otherphysical ailments, such as back pain or fibromyalgia, makes him not only uniquebut highly sought-after.

A key member of the IRMI team is Leann Emery, FNP. Emery isa family nurse practitioner with more than 20 years of experience in hormonereplacement and alternative pain management. Emery provides optimal patientcare through personal consultations and assessments to identify her patientsspecific health needs. She was rated in the top 10% of providers in the U.S.with patient satisfaction.

Regenerative medicine is making huge leaps in our understanding of the human body, and it is offering real, possible treatments that would have seemed like science fiction a few short years ago, according to IRMI. Most patients we see have tried other more traditional treatments and have either not gotten any better or have gotten even worse. Unfortunately, a lot of people we see depend on multiple medications per day to try and function but still are not happy with how they feel or how they live their lives. It is unfortunately the nature of deteriorating and degenerative joints, they will get worse with time, and generally the pain increases as well.

Depending on the injury, Dr. Peachee will often combinelaser therapy with the regenerative medicine protocols to improve the outcomesand try and speed the recovery process.

We offer mesenchymal stem cell therapy, Dr. Peachee said. With the combination of laser therapy, mesenchymal stem cell therapy is incredibly effective for rotator cuff problems and treating knee pain. Eighty percent of our stem patients are dealing with knee pain or Osteoarthritis. Osteoarthritis-or O.A. of the knee- is a huge problem for a lot of people, and we get great results from these therapies. Most people can even avoidknee surgery.

Dr. Peachee recently introduced hormone treatments for low testosterone. Family Nurse Practitioner Leann Emery has been doing [hormone] treatments for 20 years, and that area of medicine became a natural fit for IRMI.

I have several patients who were seeking this type ofcaremany who are police officers and firefighterswho couldnt find thetherapy and individualized care and attention that they needed.

Dr. Peachee explained that low T treatments help patients with unique and even complicated cases of Erectile Dysfunction (E.D.). Most people seek us out for treatment because they are tired, worn out, stressed out and just simply lack the energy they used to have.

We are able to fill a niche with patients who hadcomplicated cases that were not responding well with their primary careproviders or other places, Dr. Peachee shared. We have a patient who hasstruggled for a long time with fertility issues but has done very well [withtreatments], and we just got good news that he and his wife are expecting aftertrying for a really long time. So, he is really enthused about that.

The typical candidates for low T treatments, according toDr. Peachee, are men who feel worn out, are lethargic and have lost theirzest for life.

Our patients dont have the same pep that they had 10 or20 years ago, Dr. Peachee stated. They struggle getting up in the morning andmight be struggling in the afternoon after having six cups of coffee or threeRed Bulls just to get through the day. We have a lot of people that want to getback into the gym and get the maximum benefit of their workouts. We can helpthem improve their overall health and energy so that they can enjoyrecreational activities like working out or practice with the Little Leaguewith their kids. Many times we hear from spouses, friends and family how muchbetter they feel and that they seem happier and get more out of life again.

It goes without saying that proper hormonal balance canimprove a patients personal relationships as well and improve the overallmental health of a patient by reducing stress, anxiety and depression oftencaused by symptoms related to low testosterone levels.

We focus on injectable [low T] treatments because we canmodify the dosage and give more frequent doses to keep our patients at a levelthats going to give them the maximum benefit and improvement for theirconditions, Dr. Peachee explained.

With the modern changes in medicine over the last 20 and 50years, were helping people to live a lot longer and adding 20 to 30 years totheir lives, but we have not given them an improved quality of life as theyage. By working with their hormones and getting them in balance, their qualityof life becomes way better, and were seeing a positive improvement for manypeople with these treatments.

Patients suffering from severe disc injuries, such a bulgingor herniated disc or discs, or who suffer from degenerative disc disease mayhave undergone treatment from chiropractors or have seen physical therapistsbefore coming to Indiana Regenerative Medicine Institute.

Our typical patient who comes in for this type of treatmenthas seen other therapists or chiropractors but hasnt found lasting relief,Dr. Peachee said. Many of our patients want to get off the rollercoaster ofopioids and pain medications. They are looking for a solution without narcoticsand risk of addiction or other possible negative side effects of narcoticsand/or surgery. We are generally able to alleviate the pain in 90% of patientsand are able to keep them from having surgery or from taking addictivemedications.

Laser therapy allows Dr. Peachee to work on the damaged tissue so that it can heal, and the method reduces inflammation and swelling in a way that traditional treatments cannot.

Its an innovative new therapy within the last decade thatallows us to do some amazing things, Dr. Peachee stated. We perform ourprocedures in our office and have several different devices for the specificneeds and issues of our patients. For instance, we have a unique device forpeople with knee pain that can help the majority of our patients walk betterand live more pain-free. We get a phenomenal outcome with this procedure.

One of the other major differentiators that sets IndianaRegenerative Medicine Institute apart from other offices and clinics is thatthey are advocates for their patients, especially when it comes to dealing withtheir patients insurance providers.

A lot of our low T patients are able to get their insurancecarriers to cover the services so that it doesnt cost them as much out ofpocket for the care they seek, Dr. Peachee said. Weve partnered with abilling company that has helped us to be able to navigate the craziness of ourmodern insurance companies, and by doing so, were able to keep the cost downfor a lot of patients. Not every insurance plan will cover this type of care,but a lot of them will. When its possible and ethical, we do whatever we canto benefit our patients to help keep the cost low. I have spent a lot of freetime writing letters on behalf of our patients. We go above and beyond with ourservice and care of our patients.

The Indiana Regenerative Medicine Institute team will make housecalls or come to a patients place of work when the situation calls for thatlevel of care.

We will go and draw blood for blood work, bring medications and even do exams in some situations, Dr. Peachee said. As I mentioned before, we see a lot of police officers and firemen all over the statefrom Mishawaka to South Bend and all over Indiana. We go once a month to see these patients at their departments and stations so that we see them all in one day versus making 10 to 15 guys drive hours to come in to see us. Its a service we can offer because we are a small clinic and we are focused on that one-on-one patient attention and relationship building. We have great relationships with our patients, and thats something that we work very hard at.

Building trust and transparency is crucial to the success ofhis practice, Dr. Peachee emphasized. The trust that we build with ourpatients is crucial to not only the success of the practice but to thepatients outcomes. And not just with hormone therapy but also with ournonsurgical spinal decompression patients. These are patients with significant discinjuries, and we need them to tell us everything we need to know so we can givemore accurate and complete care for a better outcome.

I would say to anybody if you have any doubts or reservations to take some of the burden and some of the anxiety out of the equation and schedule an initial consultationabsolutely free of charge, Dr. Peachee encouraged.

Dont put off living your best life any longer. Visit Indiana Regenerative Medicine Institutes website at indianaregen.com or call (317) 653-4503 for more information about its services and specialized treatments and schedule your free consultationtoday!

Writer:

Janelle Morrison

Photography:

Laura Arick and submitted

Read more:
Indiana Regenerative Medicine Institute Offers Innovative Approaches in Regenerative Medicine, Hormone Replacement and Pain Management - Zionsville...

The most advanced study released by AMR on the Diabetic Neuropathy market comprising key market segments such as Type, Application, Sales, Growth, Comprises details of companies manufacturing field, production volume, capacities, value chain, product specifications, raw material sourcing strategies, concentration rate, organizational structure, and distribution channel.

The research is a precise offset bridging both qualitative and quantitative data of Diabetic Neuropathy market.

The study provides historical data to compare for evolving Sales, Revenue, Volume, Value of 2014 to 2019 and forecasted till 2026.

It becomes necessary to analyze the competitors progress while operating into the same competing environment, for that purpose, the report provides thorough insights into market competitors marketing strategies which include alliances, acquisitions, ventures, partnerships, as well as product launches, and brand promotions.

Some of the key and emerging players profiled in this market study profiled are Johnson & Johnson (Janssen Global Services LLC), Boehringer Ingelheim GmbH, NeuroMetrix Inc., Eli Lilly and Company, GlaxoSmithKline plc, Pfizer Inc., Lupin Limited, Astellas Pharma Inc., Glenmark Pharmaceuticals Ltd, Arbor Pharmaceuticals LLC, Depomed Inc..

Sample PDF Copy Instantly in your email box at: https://www.amplemarketreports.com/sample-request/global-diabetic-neuropathy-market-1373673.html

Diabetic Neuropathy Research objectives

Focuses on the key global Diabetic Neuropathy players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis, and development plans in the next few years.

Competitive Structure and analysis of The Diabetic Neuropathy Market:

Some of the players have a stellar growth track record for 2014 to 2018, some of these companies have shown tremendous growth by sales and revenue while net income more than doubled in the same period with performing as well as gross margins expanding. The growth in gross margins over the years points to strong pricing power by the company for its products, over and above the increase in the cost of goods sold.

The report further features analysis that contains details of companies manufacturing base, production volume, sizes, value chain, product specifications.

According to AMR, key market segments sales will traverse the $$ mark in the year 2020. Unlike classified segments by Type (), by End-Users/Application.

2020 report version is the most advanced which is further divided and highlights a new emerging twist of the industry.

Diabetic Neuropathy market will increase from $XX million in 2019 to strike $YY million by 2026, with a compound annual growth rate (CAGR) of xx%. The most robust growth is anticipated in Asia-Pacific, where CAGR is presumed to be ##% from 2019 to 2026. This prediction is good news for market players, as there is good potential for them to continue developing alongside the industrys projected growth.

Find out more on growth of Diabetic Neuropathy market at: https://www.amplemarketreports.com/report/global-diabetic-neuropathy-market-1373673.html

Market players have determined strategies to offer a whole host of new product launches within several markets around the globe. Remarkable models are variant to be launched in eight EMEA markets in Q4 2019 and 2020. Acknowledging all-around exercises some of the players profiles that would be worth reviewing are Johnson & Johnson (Janssen Global Services LLC), Boehringer Ingelheim GmbH, NeuroMetrix Inc., Eli Lilly and Company, GlaxoSmithKline plc, Pfizer Inc., Lupin Limited, Astellas Pharma Inc., Glenmark Pharmaceuticals Ltd, Arbor Pharmaceuticals LLC, Depomed Inc..

Although recent years might not be that inspiring as market segments have registered reasonable gains, things could have been better if manufacturers would have plan-driven move earlier. Unlike past, but with a decent estimate, investment cycle continuing to progress in the U.S., many growth opportunities ahead for the companies in 2020, it looks like a good for today but stronger returns can be expected beyond.

Get to know about Discount at: https://www.amplemarketreports.com/discount-request/global-diabetic-neuropathy-market-1373673.html

Report Answers Following Questions:

Thanks for reading this article, you can also get individual chapter wise section or region wise report versions like North America, Western / Eastern Europe or Southeast Asia.

With the given market data, Research on Global Markets offers customizations according to specific needs. Write to AMR at sales@amplemarketreports.com, or connect via +1-530-868-6979

About Author

Ample Market Research provides comprehensive market research services and solutions across various industry verticals and helps businesses perform exceptionally well. Our end goal is to provide quality market research and consulting services to customers and add maximum value to businesses worldwide. We desire to deliver reports that have the perfect concoction of useful data. Our mission is to capture every aspect of the market and offer businesses a document that makes solid grounds for crucial decision making.

Contact Address:

William James

Media & Marketing Manager

Address: 3680 Wilshire Blvd, Ste P04 1387 Los Angeles, CA 90010

Call: +1 (530) 868 6979

Email: sales@amplemarketreports.com

https://www.amplemarketreports.com

See the original post:
Global Diabetic Neuropathy Market 2020: What Will Be Total Market Size By 2025? - Chronicles 99

Dear Doctor: I had a rough spot on the back of my hand that turned into a wart. What caused it? How do I get rid of it?

Dear Reader: Youre describing what is known as a common wart. Its a small, raised skin growth caused by one of the estimated 150 different varieties of the human papilloma virus, or HPV. Other types of HPV cause different kinds of warts. These include plantar warts, which are callouslike growths on the soles of the feet; genital warts; and smooth, flat-topped growths known as flat warts, often seen on the face and forehead.

Common warts dont present any health dangers. However, they can be unsightly and cause embarrassment. Theyre typically about the size of a pencil eraser or smaller, may be circular or oval, and can appear anywhere on the body. Common warts may grow a smooth, domed top, or they can have a wrinkled appearance, like a head of cauliflower. Theyre often a different color than the surrounding skin, including brown, gray, pink or beige. Some may contain what look like small black dots, which are actually tiny blood vessels filled with clotted blood.

If you get a common wart, youve come into physical contact with the virus that causes it, either on someones skin, or on a surface an infected person has touched. The virus can enter the body through a break in the skin, and if your immune system cant fight it off, a wart will soon appear. Common warts are painless, but when they crack, or if you pick at them, they can bleed.

In most cases, your bodys immune system will rally, and the wart will eventually vanish, usually within a year or two. Those who would rather not wait have several treatment options. Most people can try over-the-counter wart medications available at the drug store. These are made up of salicylic acid, which is delivered either as a gel, liquid or in a patch. The acid gradually removes the layers of skin until the wart is gone. Its helpful to soak the wart in warm water prior to applying the salicylic acid, as it will allow the medication to penetrate deeper into the many layers of tissue. In between treatments, use an emery board or pumice stone to remove the dead skin. Be sure to isolate these tools since they can transmit the virus. Side effects of this treatment can include skin irritation and discomfort. Never use salicylic acid on the face or on the genitals. People living with neuropathy or diabetes should not try at-home wart removers and should see a doctor instead.

If you try a home-based treatment and its unsuccessful, your doctor also has several options available. One is that same salicylic acid, but in a higher concentration, which requires a prescription. Another approach is cryotherapy, which uses liquid nitrogen to freeze the wart. Warts may also be removed with a laser, burned off or cut away.

Any time that a wart changes shape or color, or if it becomes painful or infected, its important to seek medical attention.

Eve Glazier, M.D., MBA, is an internist and associate professor of medicine at UCLA Health. Elizabeth Ko, M.D., is an internist and assistant professor of medicine at UCLA Health.

Read the original post:
There are many ways to get rid of warts - Journal Review

The market study on the global Neuropathy Screening Devices Market will include the entire ecosystem of the industry, covering five major regions namely North America, Europe, Asia Pacific, Latin America and Middle East & Africa, and the major countries falling under those regions. The study will feature estimates in terms of sales revenue and consumption from 2019 to 2025, at the global level and across the major regions mentioned above. The study has been created using a unique research methodology specifically designed for this market.

Download Free Sample Copy of Neuropathy Screening Devices Market Report: https://dataintelo.com/request-sample/?reportId=97805

Quantitative information includes Neuropathy Screening Devices Market estimates & forecast for an upcoming years, at the global level, split across the key segments covered under the scope of the study, and the major regions and countries. Sales revenue and consumption estimates, year-on-year growth analysis, price estimation and trend analysis, etc. will be a part of quantitative information for the mentioned segments and regions/countries. Qualitative information will discuss the key factors driving the restraining the growth of the market, and the possible growth opportunities of the market, regulatory scenario, value chain & supply chain analysis, export & import analysis, attractive investment proposition, and Porters 5 Forces analysis among others will be a part of qualitative information. Further, justification for the estimates for each segments, and regions will also be provided in qualitative form.

Major Players included in this report are as follows NeuroMetrixOwen MumfordBeijing OERHUATAI TechnologyDongguan City Xinben Industrial

Neuropathy Screening Devices Market can be segmented into Product Types as Non-Electrinic DevicesElectrinc Devices

Neuropathy Screening Devices Market can be segmented into Applications as HospitalsClinicsDiagnostic CentersDrug Stores

To Buy This Report Full Or Customized, Visit https://dataintelo.com/checkout/?reportId=97805

Neuropathy Screening Devices Market: Regional analysis includes: Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia) Europe (Turkey, Germany, Russia UK, Italy, France, etc.) North America (United States, Mexico, and Canada.) South America (Brazil etc.) The Middle East and Africa (GCC Countries and Egypt.)

The study will also feature the key companies operating in the industry, their product/business portfolio, market share, financial status, regional share, segment revenue, SWOT analysis, key strategies including mergers & acquisitions, product developments, joint ventures & partnerships an expansions among others, and their latest news as well. The study will also provide a list of emerging players in the Neuropathy Screening Devices Market.

Furthermore, this study will help our clients solve the following issues: Cyclical dynamics- We foresee dynamics of industries by using core analytical and unconventional market research approaches. Our clients use insights provided by us to maneuver themselves through market uncertainties and disruptions. Identifying key cannibalizes Strong substitute of a product or service is the most prominent threat. Our clients can identify key cannibalizes of a market, by procuring our research. This helps them in aligning their new product development/launch strategies in advance. Spotting emerging trends- Our Ecosystem offering helps client to spot upcoming hot market trends. We also track possible impact and disruptions which a market would witness by a particular emerging trend. Our proactive analysis help clients to have early mover advantage. Interrelated opportunities- This report will allow clients to make decisions based on data, thereby increasing the chances that the strategies will perform better if not best in real world.

Customize Report and Inquiry for The Neuropathy Screening Devices Market Report: https://dataintelo.com/enquiry-before-buying/?reportId=97805

This study will address some of the most critical questions which are listed below: What is the market size of the Neuropathy Screening Devices Market at the global level? Which mode of distribution channel is most preferred by the manufacturers of Neuropathy Screening Devices? Which is the preferred age group for targeting Neuropathy Screening Devices for manufacturers? What the key factors driving, inhibiting the growth of the market, and what is the degree of impact of the drivers and restraints? What is the impact of the regulations on the growth of the Neuropathy Screening Devices Market? Which is the leading region/country for the growth of the market? What is the anticipated growth rate of the leading regions during the forecast period? How are the emerging markets for Neuropathy Screening Devices expected to perform in the coming years? How is the consumption pattern expected to evolve in the future? Who are the major players operating in the global Neuropathy Screening Devices Market? What is the current market position of the key players? Who are the emerging players in this industry? Who are the major distributors, traders, and dealers operating in the Neuropathy Screening Devices Market?

Request For Discount Copy: https://dataintelo.com/ask-for-discount/?reportId=97805

About DataIntelo: DATAINTELO has set its benchmark in the market research industry by providing syndicated and customized research report to the clients. The database of the company is updated on a daily basis to prompt the clients with the latest trends and in-depth analysis of the industry. Our pool of database contains various industry verticals that include: IT & Telecom, Food Beverage, Automotive, Healthcare, Chemicals and Energy, Consumer foods, Food and beverages, and many more. Each and every report goes through the proper research methodology, validated from the professionals and analysts to ensure the eminent quality reports.

Contact Info DataIntelo Name Alex Mathews Email [emailprotected] Website https://dataintelo.com Address 500 East E Street, Ontario, CA 91764, United States.

Original post:
Neuropathy Screening Devices Market Trends, Key Players, Overview, Competitive Breakdown and Regional Forecast by 2025 - News Parents

Global Medical Foods Market: Overview

One of the key factors boosting the growth of the global medical foods market is the rising awareness among the people regarding medical foods. The rising focus of the regulatory bodies on the manufacturing and labelling of medical foods will also be a key factor fuelling the growth of the medical foods market. In addition to this, the high focus by manufacturers on developing disease-specific formulas effective patients nutrition or diet care are also anticipated to result in the growth of the global medical foods market.

The report also enlists various factors which are anticipated to pose a challenge for the growth of the market. The current trends in the market and those that are anticipated to shape the future of the market have been discussed in detail in the report.

Get Sample Copy of the Report @https://www.tmrresearch.com/sample/sample?flag=B&rep_id=2558

By product, the medical food market is segmented into powder, pill, and others. Of these the powder segment has held a key share in the market as many medical food products are manufactured in powdered form and consumed in a semi solid or liquid form. By application, the global medical foods market is segmented into depression, diabetic neuropathy, ADHD, Alzheimers disease, and nutritional deficiency. Of these, diabetic neuropathy has been accounting for key shares within the market. The risk of neuropathy is boosted with age, diet changes, and unhealthy lifestyle.

In the years to come, it is anticipated that the nutritional deficiencies segment will develop a strong CAGR, as patients being treated for ADHD, autoimmune diseases, and cancer are likely to have high nutritional requirements, which is subsequently anticipated to boost the demand for medical foods.

Global Medical Foods Market: Snapshot

The global medical foods market has become increasingly important in the healthcare sector in recent years due to the rising awareness about its importance in complementing the treatment. Medical food comprises diets designed specifically to overcome the nutritional deficiencies caused by some diseases or to fulfill the specific dietary needs in the management of some diseases. The global medical foods market is likely to receive steady support from the healthcare sector in the coming years due to the rising prevalence of diseases such as Alzheimers among the elderly and ADHD among children, as these diseases are among the prime diseases that necessitate specific diet plans.

Request TOC of the Report @https://www.tmrresearch.com/sample/sample?flag=T&rep_id=2558

Global Medical Foods Market: Key Trends

The rising geriatric population is a major driver for the global medical foods market. Old people are more likely to develop nutritional disorders as well as to fall prey to other diseases that affect their ability to absorb nutrients from their diet. Nutrition deficiency disorders are also more common among the geriatric demographic than in other patient classes, leading to the geriatric population becoming a key consumer segment for the global medical foods market.

The increasing prevalence of diabetes across the world is another key driver for the global medical foods market. Diabetic neuropathy is the leading application of the global medical foods market and is likely to retain dominance in the coming years. Diabetic neuropathy is becoming common among diabetic patients due to their often unhealthy lifestyles, with close to three-quarters of all diabetes likely to also suffer from some form of neuropathy. This is a key driver for the global medical food market, as the rising prevalence of diabetes in emerging regions has, in conjunction with the rising investment in the healthcare sector, created a conducive environment for growth of the market.

The rising prevalence of ADHD among children is also likely to remain a key driver for the global medical foods market. The growing prevalence of the disease has led to intensive research into its causation and treatment. The role of nutrition in the management of psychological problems such as ADHD has thus come under the scanner. On the opposite end of the spectrum, the rising prevalence of neurodegenerative conditions among the geriatric population is also likely to remain a key driver for the global medical foods market in the coming years.

Global Medical Foods Market: Market Potential

The global medical foods market is likely to witness a steady shift towards pills and away from powders. While powders can be easily mixed with various types of food, many patients dont enjoy their taste. This has led to pills becoming a preferred mode of delivery for many, and are thus likely to rise in demand in the global medical foods market in the coming years.

Apart from leading diseases such as diabetic neuropathy and Alzheimers, other diseases such as phenylketonuria (PKU) are also likely to come under the ambit of the medical food market in the coming years. In April 2017, PKU Sphere, a new medical food for patients of PKU was launched. PKU Sphere is claimed to contain a balanced mix of amino acids and glycomacropeptide, a protein essential for patients of PKU, who cant digest phenylalanine and have to fulfill their protein requirements in alternate ways.

Global Medical Foods Market: Geographical Dynamics

North America is likely to remain the leading regional contributor to the global medical foods market in the coming years due to the ready availability of advanced healthcare technology and a solid database regarding the dietary needs of patients suffering from various diseases. The rising prevalence of diabetes in North America, due primarily to the unhealthy lifestyle practiced by citizens in developed countries such as the U.S., is also likely to be crucial for the medical foods market in North America in the coming years.

Global Medical Foods Market: Competitive Dynamics

The leading players in the global medical foods market include Abbott, Fresenius Kabi AG, Targeted Medical Pharma Inc., Danone, and Primus Pharmaceuticals Inc. The steady support to development of sophisticated disease-specific formulas is likely to benefit the medical foods market in the coming years.

Read Comprehensive Overview of Report @https://www.tmrresearch.com/medical-foods-market

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

TMR Research,

3739 Balboa St # 1097,

San Francisco, CA 94121

United States

Tel: +1-415-520-1050

Excerpt from:
Medical Foods Market Analysis Trends and Dynamic Demand by Forecast 2017 to 2025 - Jewish Life News

The Global Neuropathic Pain Drug Market is expected to grow from USD 7,598.48 Million in 2018 to USD 13,938.27 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 9.05%.

The report contains a wide-view explaining Neuropathic Pain Drug Market on the global and regional basis. Global Neuropathic Pain Drug market report is a definitive source of information and provides latest market research intelligence, changing consumer trends with actionable insights on emerging players, products, and technologies. Our analysts possess statistical data to provide insights on statistical report including the factors responsible for driving and hindering the growth of the market along with the impact theyll have on the demand over the coming years.

The study is a combined effort of primary as well as secondary research. The report gives insights on the key factors concerned with generating and limiting Neuropathic Pain Drug industry growth. Additionally, the report also studies competitive developments, such as mergers and acquisitions, new partnerships, new contracts, and new product developments in the global Neuropathic Pain Drug market. The past trends and future prospects included in this report makes it highly comprehensible for the analysis of the market. Moreover, the latest trends, product portfolio, demographics, geographical segmentation, and regulatory framework of the Neuropathic Pain Drug market have also been included in the study.

Neuropathic Pain Drug industry competition by top manufacturers/ Key player Profiled:Bristol-Myers Squibb and Company, Eli Lily and Company, GlaxoSmithKline PLC, Johnson & Johnson Services Inc., Pfizer Inc., Baxter Healthcare Corporation, Biogen Idec Inc., Depomed Inc., and Sanofi S.A.. On the basis of Type, the Global Neuropathic Pain Drug Market is studied across Phantom Limb Pain, Post Herpetic Neuralgia, Post-traumatic Neuropathy, and Trigeminal Neuralgia.

On the basis of Treatment, the Global Neuropathic Pain Drug Market is studied across Antidepressant Drugs Type, Medication Type, Multimodal Therapy, and NSAIDs Type.

On the basis of Indication, the Global Neuropathic Pain Drug Market is studied across Diabetic Neuropathy and Spinal Stenosis.

On the basis of Diagnosis, the Global Neuropathic Pain Drug Market is studied across Blood Tests and Imaging Physical Examination.

On the basis of Distribution, the Global Neuropathic Pain Drug Market is studied across Online Pharmacies and Retail Pharmacies & Drug Stores.

On the basis of End User, the Global Neuropathic Pain Drug Market is studied across Clinics and Hospitals.

Get a Sample PDF of report @ https://www.regalintelligence.com/request-sample/24893

Scope of the Neuropathic Pain Drug Market Report:

APAC is expected to dominate the global Neuropathic Pain Drug market during the forecast period. The worldwide market for Neuropathic Pain Drug is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2025, from xx million US$ in 2019, according to the study. This report focuses on the Neuropathic Pain Drug in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa.

The next part also sheds light on the gap between supply and consumption. Apart from the mentioned information, growth rateofNeuropathic Pain Drugmarket in 2025is also explained. Additionally, type wise and application wise consumptiontables andfiguresof Neuropathic Pain Drugmarketare also given.

Objective of Studies:

Report on Global Neuropathic Pain Drug Industry 2019 mainly covers 10 Section in Table as follows:-

Look into Table of Content of Neuropathic Pain Drug Industry Report @ https://www.regalintelligence.com/request-toc/24893

Contact Us:Regal Intelligencewww.regalintelligence.comsales@regalintelligence.comPh no: +1 231 930 2779 (U.S.)

Follow Us:https://in.linkedin.com/company/regal-intelligencehttps://www.facebook.com/regalintelligence/https://twitter.com/RI_insights

Continued here:
The Global Neuropathic Pain Drug Market is expected to grow from USD 7,598.48 Million in 2018 to USD 13,938.27 Million by the end of 2025 at a...

A team of researchers from the NUS Yong Loo Lin School of Medicine has identified a novel protein that would prevent the development of neuropathy in cancer patients who receive chemotherapy.

Chemotherapy is one of the most commonly recommended treatments for many forms of cancer. One major side effect, however, is peripheral neuropathy, or the damage or dysfunction of one or more nerves that typically results in numbness, tingling, muscle weakness and pain in the affected area. It frequently starts in a patient's hands and feet, though other regions and parts of the body can also be affected.

At the moment, there is no way to prevent or treat neuropathy caused by chemotherapy drugs. The only option is to limit or discontinue the chemotherapy treatment. As a result, many patients are not able to tolerate chemotherapy well.

In a recent study published by theJournal of Biological Chemistry, a team of researchers jointly led by Assistant Professor Raymond Deron Herr and Assistant Professor Raghav Sundar from the NUS Yong Loo Lin School of Medicine set out to examine whether S1P2, a receptor protein that resides on the surface of cells in the nervous system, is a potential target in the treatment of chemotherapy-induced neuropathy. The team first looked at the effects of platinum-based chemotherapy drugs, such as cisplatin, on the regulation of S1P2 and found that chemotherapy alters S1P2 activity. The team further demonstrated that the activation of S1P2 with a drug-like compound, can protect the nerve cells from damage and pain. This is in contrast to the accumulation of free radicals in nerves, leading to nerve degeneration when the receptor is removed. The team concluded that it is possible to block both the nerve injury and the pain when S1P2 is activated with a drug while administering cisplatin.

There are three major classes of drugs that cause neuropathy: platinum compounds (cisplatin and oxaliplatin), taxanes (paclitaxel), and a targeted medication known as bortezomib.

"While the study focused on the effects of cisplatin, based on what we know about the molecular processes, it is likely that an S1P2 drug will work in all cases of chemotherapy-induced neuropathy. Furthermore, it is possible that such a drug could treat many other forms of neuropathy, such as those caused by nerve injury, autoimmune disease, or diabetes," said Dr Herr.

"Neuropathy or numbness from chemotherapy is a common and debilitating side-effect faced by patients, with few proven treatments. Our study provides a deeper understanding of the biology of this condition, allowing potential treatments to reduce chemotherapy-induced neuropathy to be developed. We are currently exploring new drug molecules that would allow the activation of S1P2 in a more effective and stable manner," added Dr Sundar, who is also a Consultant with the Department of Haematology-Oncology at the National University Cancer Institute, Singapore (NCIS) and the National University Hospital.

Reference: Wang, et al. (2020) Activation of sphingosine 1-phosphate receptor 2 attenuates chemotherapy-induced neuropathy. Journal of Biological Chemistry DOI:10.1074/jbc.RA119.011699

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Continued here:
Protein Prevents Neuropathy From Chemotherapy - Technology Networks

High levels of glucose in the blood can damage the peripheral nerves in your body, causing decreased sensation in the feet and hands as well as problems to the urinary tract, digestive system, and heart. With over 60 per cent of diabetics eventually developing peripheral neuropathy, it is one of the main secondary complications they face. Mild to moderate symptoms include pain, numbness and tingling sensation in the feet and legs. Fortunately, diabetic neuropathy can be prevented if strict control is maintained on blood sugar levels on a daily basis. Lifestyle changes and complementary therapies can help achieve this effectively. Three of the most commonly practiced alternative therapies to help prevent diabetic neuropathy are naturopathy, yoga and acupuncture.

Acupuncture

Acupuncture uses the science of inserting long, fine needles at various points in the body to stimulate the sensory receptors and stimulate them. A study published in the Journal of Thai Traditional and Alternative Medicine found that acupuncture drastically improves the positive effects of diabetes medication and alleviates the symptoms of diabetic neuropathy. Once they started the acupuncture regimen, the success rate of the symptom score went up from 8 percent to 90 per cent. The neuropathic disability score also went up from 37.45 to 90 once acupuncture was introduced into the treatment regimen.

Naturopathic and yogic interventions to improve diabetic neuropathy

Diet and exercise: The best defense against progressive damage from diabetic neuropathy is to manage the disease itself. Keep your blood sugar levels in check by eating healthy. Ensure that your diet includes a lot of fiber rich foods and whole grains, and very little saturated and trans fats. Structured physical interventions also play an important role in keeping blood sugar levels in check. Make sure you get at least 30 minutes of aerobic exercise every day. Meditation and deep breathing can help you manage chronic stress.

Supplements: Winter ginseng is very effective at keeping the blood sugar in control and managing the symptoms of peripheral neuropathy. Not only does it help increase the level of serum insulin, it also improves the insulin sensitivity of muscle cells as well as the bodys glucose tolerance, thereby easing the severity of diabetic neuropathy.

Yoga poses for the management of neuropathy

Yoga helps improve blood flow to the extremities, improves the bodys glucose tolerance and insulin sensitivity.

Exercise for feet and hands: Sit down in padmasana and extend your arms fully in front of your chest. This pose will help stretch both fingers and toes. It will help improve blood flow to the periphery and strengthen your nerves. If you can do it for a few minutes every day, you will start to experience relief.

Poses for diabetic neuropathy: If the condition is not severe, then traditional hatha yoga poses like trikonasana, ustrasana and dhanurasana will do. If the neuropathy is more advanced, it needs gentler practice under the guidance of a trained instructor. However, you can still benefit from gentle twist exercises, meditation and closely supervised backbends.

More:
Yoga to acupuncture: Alternative therapies to prevent diabetic neuropathy - Business Standard

The report titled Global Chemotherapy Induced Peripheral Neuropathy Treatment Market is one of the most comprehensive and important additions to Reportspedia archive of market research diaries. It offers thorough research and analysis of major aspects including market size, market growth rate, market profitability, industry cost structure, distribution channel, market trends, and key success factors of the market.

The report includes SWOT and PESTLE analyses to provide a deeper understanding of the industry. All of the foremost companies included in the report are profiled based on gross margin, market share, forthcoming strategies, recent expansions, target customer demographics, products and applications, and other critical factors. The report also offers regional analysis of the Chemotherapy Induced Peripheral Neuropathy Treatment market with high focus on market growth, growth rate, and growth potential.

Global Chemotherapy Induced Peripheral Neuropathy Treatment Market is valued at USD XX million in 2019 and is projected to reach US$ XX million till 2025, rising at a CAGR of 6.2% during the period 2019 to 2025.

Major Players involved in the Global Chemotherapy Induced Peripheral Neuropathy Treatment Market:

Aptinyx Inc, Sova Pharmaceuticals Inc, MAKScientific LLC, Asahi Kasei Pharma Corp, PledPharma, Regenacy Pharmaceuticals, Immune Pharmaceuticals Inc, Nemus Bioscience Inc, Metys Pharmaceuticals AG, DermaXon LLC, WinSanTor, Kineta Inc, Solasia Pharma K.K., Apexian Pharma, Krenitsky Pharmaceuticals Inc, PeriphaGen,

Get Free PDF Sample Report(Including Full TOC, List of Tables & Figures, Chart):https://www.reportspedia.com/report/life-sciences/global-chemotherapy-induced-peripheral-neuropathy-treatment-market-2020-by-manufacturers,-regions,-type-and-application,-forecast-to-2025/49368#request_sample

Market Competition

The vendor landscape and competitive scenarios of the global Chemotherapy Induced Peripheral Neuropathy Treatment industry are broadly analyzed to help market players gain competitive advantage over their competitors. Market players can use the analysis to prepare themselves for any future challenges well in advance. They will also be able to identify opportunities to attain a position of strength in the global Chemotherapy Induced Peripheral Neuropathy Treatment industry. Furthermore, the examination will help them to successfully channelize their strategies, strengths, and resources to gain maximum advantage.

The Essential Content Covered in the Global Chemotherapy Induced Peripheral Neuropathy Treatment Industry Report:

* Top Key Company Profiles.

* Main Business and Rival Information

* SWOT Analysis and PESTEL Analysis

* Production, Sales, Revenue, Price and Gross Margin

* Market Share and Size

The Chemotherapy Induced Peripheral Neuropathy Treatment Industry segment by regions includes:

Americas (United States, Canada, Mexico, and Brazil), APAC (China, Japan, Korea, Southeast Asia, India, and Australia), Europe (Germany, France, UK, Italy, Russia, and Spain), and Middle East & Africa (Egypt, South Africa, Israel, Turkey, and GCC Countries).

Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Segmentation by Product:

By Type Chemotherapy Induced Peripheral Neuropathy Treatment market has been segmented into Calcium Channel 2-delta Ligands, Antidepressants, Opioids, Others, etc.

Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Segmentation by Application:

By Application Chemotherapy Induced Peripheral Neuropathy Treatment has been segmented into Platinum Agents, Taxanes, Vinca Alkaloids, Others, etc.

Inquire Here For Queries Or Report Customization: : https://www.reportspedia.com/report/life-sciences/global-chemotherapy-induced-peripheral-neuropathy-treatment-market-2020-by-manufacturers,-regions,-type-and-application,-forecast-to-2025/49368#inquiry-before-buying

Key Questions Answered

1) What will be the size and CAGR of the global Chemotherapy Induced Peripheral Neuropathy Treatment market in 2025?

2) Which product will gain the highest request?

3) Which application could show the best development/growth?

4) What will be the competitive landscape in future?

5) Which players will lead the global Chemotherapy Induced Peripheral Neuropathy Treatment market in the coming years?

6) Which region will gain the largest share of the industry?

The report offers comprehensive analysis of the value chain, production, consumption, sales, and opportunities in the global Chemotherapy Induced Peripheral Neuropathy Treatment market. Market players can also use it to get useful endorsements and suggestions from market experts and knowledgeable industry analysts.

Table of Contents

Executive Summary

1 Industry Overview

2 Industry Chain Analysis

3 Manufacturing Technology of Chemotherapy Induced Peripheral Neuropathy Treatment market

4 Major Manufacturers Analysis

5 Global Productions, Revenue and Price Analysis of Chemotherapy Induced Peripheral Neuropathy Treatment market by Regions, Creators, Types and Applications

6 Global and Foremost Regions Capacity, Production, Revenue and Growth Rate of Chemotherapy Induced Peripheral Neuropathy Treatment industry 2015-2019

7 Consumption Volumes, Consumption Value, Import, Export and Trade Price Study of Chemotherapy Induced Peripheral Neuropathy Treatment market by Regions

8 Gross and Gross Margin Examination

9 Marketing Traders or Distributor Examination

10 Worldwide Impacts on Chemotherapy Induced Peripheral Neuropathy Treatment Industry

11 Development Trend Analysis

12 Contact information

13 New Project Investment Feasibility Analysis

14 Conclusion of the Global Chemotherapy Induced Peripheral Neuropathy Treatment Industry 2019 Market Research Report

Continued

Click here to view the full report:https://www.reportspedia.com/report/life-sciences/global-chemotherapy-induced-peripheral-neuropathy-treatment-market-2020-by-manufacturers,-regions,-type-and-application,-forecast-to-2025/49368#table_of_contents

Visit link:
Global Chemotherapy Induced Peripheral Neuropathy Treatment Market 2020 Research Report by Manufactures, Types, Applications and Forecast to 2025 ...

Qin Yang, Yingxiao Zhang, Qinglian Zeng, Chan Yang, Jiale Shi, Chunlin Zhang, Xia Ni, Zhipeng Du, Ziwei Tang, Jinbo Hu, Xuemei Li, Jiahui Cai, Qifu Li, Qingfeng Cheng

Department of Endocrinology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, Peoples Republic of China

Correspondence: Qingfeng ChengThe First Affiliated Hospital of Chongqing Medical University, No. 1, Youyi Road, Yuanjiagang, Yuzhong District, Chongqing 400042, Peoples Republic of ChinaTel +86-23-89011510Fax +86-23-890115540Email cqf19760516@163.com

Purpose: The present study was designed to determine the relationships between sarcopenia and diabetic peripheral neuropathy (DPN) in patients with type 2 diabetes mellitus (T2DM) and diabetic foot disease (DFD) respectively.Patients and Methods: A total of 1104 patients with T2DM and 257 patients with DFD were included in the study, which was designed as a cross-sectional study. Body composition was assessed using dual-energy X-ray-absorptiometry (DXA). The diagnosis of sarcopenia was based on the Baumgartner criteria. DPN was assessed by Neuropathy symptom score (NSS) and Neuropathy disability score (NDS), and the severity of neuropathy was divided into non-neuropathy symptom (NS), Mild NS, Moderate NS and Severe NS according to NSS. Logistic regression analyses were carried out to determine the relations of sarcopenia and DPN in patients with T2DM and NSS in patients with DFD, respectively.Results: The prevalence of DPN was 80.0% in T2DM patients with sarcopenia and 70.3% in non-sarcopenia patients (P=0.007). Logistic regression analyses showed DPN was one of the independent risk factors for sarcopenia in T2DM patients (OR 1.564 [95% CI: 1.004, 2.435], P=0.048). The prevalence of DPN had no statistical significance in DFD patients with or without sarcopenia. However, the NSS of DFD patients with sarcopenia was higher than that of non-sarcopenia patients. In the multivariate logistic regression analysis, NSS was determined to be associated with sarcopenia in DFD patients (OR 1.387[95% CI: 1.074, 1.789], P=0.012). The appendicular lean mass (ALM) of DFD patients without NS was higher than patients with mild, moderate and severe NS (20.71 2.73 vs 16.57 3.62 vs 17.99 3.54 vs 17.23 3.29 Kg, P=0.028).Conclusion: DPN is an independent risk factor for sarcopenia in patients with T2DM and NSS is also independently correlated with sarcopenia in patients with DFD, with the latter being more obvious with the aggravation of neurological symptoms in DFD patients.

Keywords: type 2 diabetes mellitus, diabetic peripheral neuropathy, diabetic foot disease, sarcopenia, correlation

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Continued here:
Correlation Between Diabetic Peripheral Neuropathy and Sarcopenia in P | DMSO - Dove Medical Press

Diabetic Neuropathy: High sugar ranges in blood can result in many ailments. One of its severe results is nerve injury ( Nerve injury ) is. In medical phrases its known as diabetic neuropathy ( Diabetic Neuropathy ) is known as. Diabetic neuropathy strikes the nerves of your toes and legs.

->But it might probably additionally have an effect on the fingers and arms. You might really feel ache and numbness. Sometimes, a tingling in your toes and toes can be an indication of this situation. It can have an effect on your digestive system, blood vessels, urinary tract in addition to your coronary heart. Therefore, it turns into essential to protect in opposition to it in time.

To keep away from nerve injury its essential to preserve blood sugar ranges beneath management. If its ignored for too lengthy, it might probably trigger incapacity. In very extreme circumstances, it is usually prone to trigger amputation of the limbs. The most harmful factor is that you could be not even know that youre experiencing nerve injury till its too late. This is as a result of the signs can generally be deceptive. Let us know how you can stop such sort of nerve injury in diabetes

Control your blood sugar stageControlling blood sugar ranges is the primary rule to forestall diabetic neuropathy. Keep your blood sugar ranges inside regular limits. If it fluctuates, discuss to your physician. He can change your medication. But, in your half, you must always monitor your blood sugar stage. You can simply do that at residence with a blood sugar meter. Also you should definitely go for the A1C take a look at each six months.

Take care of your toesYour toes are essential. It is essential to care for them. If nerve injury has already occurred, then you could be alert for any harm. This is as a result of you arent prone to really feel ache, your harm might trigger issues. Cut your nails commonly and pat your toes. Use lotion and apply it between your toes as effectively. Wash your toes with heat water and cleaning soap. Dry them effectively. Talk to your physician if you could put on any particular footwear for diabetic neuropathy. Even if it isnt obligatory, all the time put on comfy footwear.

Exercise safelyTalk about exercising in case of diabetes, then observe some guidelines. If you might be jogging or working, put on good high quality trainers. Some actions will not be good for you. Seek the recommendation of a educated skilled earlier than beginning any new train.

Read more:
This methodology reduces the danger of diabetes neuropathy in diabetes - Sahiwal Tv